Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;35(11):1570-1577.
doi: 10.1038/s41379-022-01105-8. Epub 2022 Jun 8.

The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma

Luvy D Mendez  1 , Nicholas S Wolsefer  2 , Sylvia L Asa  1 , Jay Wasman  1 , Jennifer M Yoest  1 , Ivan J Stojanov  3   4
Affiliations
Free article

The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma

Luvy D Mendez et al. Mod Pathol. 2022 Nov.
Free article

Abstract

Ameloblastoma is a benign, locally aggressive odontogenic neoplasm with variable solid and cystic morphology. On account of its histologic variety, diagnostically challenging cases can bear resemblance to odontogenic keratocyst/keratocystic odontogenic tumor (KCOT) or dentigerous cyst (DC). BRAFV600E mutation has been reported to be specific for and frequent in ameloblastoma, and this study evaluated the usefulness of immunohistochemistry (IHC) using the BRAF VE1 mutant-specific antibody as a diagnostic adjunct in this setting. We investigated 46 ameloblastomas, 30 KCOTs, and 30 DCs. BRAF VE1 IHC was performed on all cases and allele-specific polymerase chain reaction (AS-PCR) for BRAFV600E mutation was performed on 30 ameloblastomas and any IHC-positive KCOT/DC. BRAF VE1 IHC was positive in 31/37 (83.8%) mandibular ameloblastomas but not in any maxillary ameloblastomas (0/9), KCOT (0/30), or DC (0/30). Equivocal staining was seen in 1/37 (3.3%) mandibular ameloblastomas. Of the 30 ameloblastomas subjected to AS-PCR, BRAFV600E mutation was identified in 19/23 (82.6%) mandibular ameloblastomas and 0/7 (0.0%) maxillary ameloblastomas. BRAFV600E mutant ameloblastomas were positive by IHC in 18/19 (94.7%) cases and equivocal in 1/19 (5.3%) cases. All 11 (100.0%) BRAF-wild type ameloblastomas were negative by IHC. BRAF VE1 is an excellent tool for the diagnosis of mandibular ameloblastoma but of limited utility in the maxilla, where it less commonly occurs and where BRAFV600E mutation is considerably less frequent.

PubMed Disclaimer

References

    1. Reichart, P. A., Philipsen, H. P. & Sonner, S. Ameloblastoma: biological profile of 3677 cases. Eur J Cancer B Oral Oncol 31B, 86–99 (1995).
    1. Li, T. J., Wu, Y. T., Yu, S. F. & Yu, G. Y. Unicystic ameloblastoma: a clinicopathologic study of 33 Chinese patients. Am J Surg Pathol 24, 1385–1392 (2000).
    1. DeVilliers, P., Liu, H., Suggs, C., Simmons, D., Daly, B., Zhang, S. et al. Calretinin expression in the differential diagnosis of human ameloblastoma and keratocystic odontogenic tumor. Am J Surg Pathol 32, 256–260 (2008).
    1. Cairns, L., Naidu, A., Robinson, C. M., Sloan, P., Wright, J. M. & Hunter, K. D. CD56 (NCAM) expression in ameloblastomas and other odontogenic lesions. Histopathol 57, 544–548 (2010).
    1. Kusafuka, K., Hirobe, K., Wato, M., Tanaka, A. & Nakajima, T. CD56 expression is associated with neuroectodermal differentiation in ameloblastomas: an immunohistochemical evaluation in comparison with odontogenic cystic lesions. Med Mol Morphol 44, 79–85 (2011).

Publication types

LinkOut - more resources